2026年8月19日 22:00 ET 发布 · 更新于 3 个月前 · 1 个来源
Moderna's personalized mRNA vaccine success in melanoma treatment is a significant positive catalyst
Youtube
·
原始报道
Moderna's personalized mRNA vaccine, developed with Merck, demonstrated a 50% reduction in melanoma recurrence and spread when added to Keytruda in Phase 3 trials, which is an amazing positive outcome and a significant catalyst for the company.
原文